Pyxis Oncology is trading 5.32% down at $2.85 as investors continue reassessing its August 13, 2026 quarterly results and $25.3 million second-quarter net loss.
- The company missed analyst EPS expectations and reported sharply higher general and administrative expenses.
- Financing extended its cash runway into 2027.
- Investors await clinical updates later in 2026.